Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE reverses Alzheimer's drug decision

  • Comment

The National Institute for Health and Clinical Excellence (NICE) has extended the use of three drugs to treat Alzheimer’s disease.

Aricept, exelon and reminyl - which are currently available through the NHS to sufferers of the condition who have moderate to severe symptoms - have now been approved for patients with milder problems.

A fourth drug - ebixa - will be extended to people suffering more moderate symptoms after only previously being given to those in the late stages of the disease, NICE has confirmed.

The extension has proved to be a u-turn from the drugs rationing body which has reversed its original guidance from four years ago, which resulted in a campaign for the decision to be changed.

The drugs cost around £2.80 per patient per day, slowing down progression of the condition, and meaning patients can continue to recognise their loved ones or remain independent in their own homes for longer.

Have you signed our petition to ensure nurses have a seat on consortia boards? Follow @Aseatontheboard on twitter follow for all the latest campaign news!

 

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs